BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38622276)

  • 1. Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma.
    Cho O; Chun M; Chang SJ
    Sci Rep; 2024 Apr; 14(1):8710. PubMed ID: 38622276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
    Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
    Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
    Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis.
    Choi KH; Yu M; Jeong S; Lee JH
    Int J Clin Oncol; 2020 Jul; 25(7):1405-1411. PubMed ID: 32221801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
    Zhang G; Miao L; Wu H; Zhang Y; Fu C
    Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
    [No Abstract]   [Full Text] [Related]  

  • 8. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
    Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
    Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
    J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer.
    Fu J; Wang W; Wang Y; Liu C; Wang P
    Radiat Oncol; 2019 Aug; 14(1):146. PubMed ID: 31416463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
    Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
    Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
    Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
    Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
    J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of pretreatment SUV
    Shou H; Yasuo Y; Yuan S; Lou H; Ni J
    Int J Gynaecol Obstet; 2021 Jan; 152(1):112-117. PubMed ID: 33141954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
    Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
    Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
    Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
    Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study.
    Guo Q; Zhu J; Wu Y; Wen H; Xia L; Wu X; Ju X
    Eur J Surg Oncol; 2020 Jan; 46(1):131-138. PubMed ID: 31481274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
    Li D; Xu XX; Yan DD; Yuan SH; Lou HM
    Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
    Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.